Brooks C D, Karl K J
Clinical Investigation Unit, Bronson Methodist Hospital, Kalamazoo, MI 49007.
J Allergy Clin Immunol. 1988 Jun;81(6):1110-7. doi: 10.1016/0091-6749(88)90877-9.
Twenty-eight ragweed-allergic patients with hay fever participated in a clinical trial that examined the pattern of symptom relief resulting from addition of a cyclooxygenase-inhibiting drug to standard antihistamine therapy. In the first week antihistamine use by the subjects was standardized, and subjects were oriented to use of the hay fever symptom diary. They were then allocated, according to symptom severity, to two treatment groups. One group received 120 mg of terfenadine and 300 mg of flurbiprofen (a cyclooxygenase-inhibiting drug) per day. Members of the other group received terfenadine and a placebo that looked like flurbiprofen. This treatment lasted 1 week. Subjects recorded severity of congestion, drainage, running, nose blowing, itching, and sneezing four times each day. The flurbiprofen-treated patients experienced less severe symptoms, demonstrating maximum benefit 3 to 5 days into the drug trial with some loss of effect thereafter. Secretion-related symptoms appeared to benefit most. Combined blockade of histamine and cyclooxygenase products appears to offer improved symptom control in ragweed hay fever.
28名患有花粉热的豚草过敏患者参与了一项临床试验，该试验研究了在标准抗组胺治疗中添加一种环氧化酶抑制药物后症状缓解的模式。在第一周，受试者的抗组胺药物使用标准化，并且指导受试者使用花粉热症状日记。然后，根据症状严重程度将他们分为两个治疗组。一组每天服用120毫克特非那定和300毫克氟比洛芬（一种环氧化酶抑制药物）。另一组受试者服用特非那定和看起来像氟比洛芬的安慰剂。这种治疗持续1周。受试者每天记录四次鼻塞、流涕、流鼻涕、擤鼻、瘙痒和打喷嚏的严重程度。接受氟比洛芬治疗的患者症状较轻，在药物试验的第3至5天显示出最大益处，此后效果有所下降。与分泌物相关的症状似乎受益最大。组胺和环氧化酶产物的联合阻断似乎能更好地控制豚草花粉热的症状。
